Working… Menu
Trial record 57 of 121 for:    prostate cancer AND prostate cancer screening | ( Map: United States )

11C Acetate Imaging Post Prostatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01602783
Recruitment Status : Terminated (Slow accrual; no further funding)
First Posted : May 21, 2012
Last Update Posted : March 18, 2014
Information provided by (Responsible Party):
Umar Mahmood, Massachusetts General Hospital

Brief Summary:

This research is being conducted to test an imaging technique that may be able to detect small amounts of prostate cancer that can not be detected by standard imaging.

Many patients who are diagnosed with prostate cancer undergo surgery to remove the prostate. After this surgery, some patients have a PSA blood test that reveals a low but detectable level of PSA. This PSA may be produced by cancer cells in one of two locations: (1) near the area where the prostate used to be, or (2) elsewhere in the body. If the cancer is only in the area where the prostate used to be, it can be successfully treated with radiation to that area. If the cancer is elsewhere, radiation is not helpful. Currently, there is no available scan that can detect cancer when the PSA is still so low.

The test used in this study is called [11C] acetate PET screening. [11C] acetate is a radioactive tracer that is given by vein to patients before PET scanning. The PET scanner then detects radioactivity from the tracer that is attached to cells within your body and uses this information to create images (pictures) on a computer screen.

[11C] acetate PET scanning has been shown in early studies to detect smaller amounts of prostate cancer that can be detected by standard imaging tests such as CT scan and bone scan. If it is successful at detecting very small amounts of prostate cancer, [11C] acetate PET scanning will help doctors identify patients who will benefit from radiation therapy after their prostate has been surgically removed. It will also help them identify patients who have small amounts of prostate cancer in other parts of the body and will not benefit from radiation to the prostate area.

This type of PET scan is investigational. "Investigational" means that the scan is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved this type of PET scan for your type of cancer. The information collected by this scan will determine whether this type of scanning is helpful but it will not be used to make decisions about your medical care.

Condition or disease Intervention/treatment Phase
Prostate Cancer Other: 11C Acetate Imaging Not Applicable

Detailed Description:

If you decide to participate in the study and are eligible, you will undergo a single [11C] acetate PET scan. This scan is designed to detect small amounts of your tumor that were not detected by the CT scan or the bone scan. On the day of the scan, you will fast for at least four hours prior to being given the tracer injection by vein. You will then be scanned in the PET scanner. The entire procedure will take approximately 2 hours.

The investigators would like to keep track of your medical condition after you have completed your scan. The investigators would like to do this by looking up information in your medical record during the year following the scan to see how you are doing. Checking your condition helps us understand whether the [11C] acetate PET scan will be helpful to other patients in the future.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Use of 11C Acetate Imaging for Improved Prediction of the Effectiveness of Salvage Pelvic Radiation Post Prostatectomy: A Pilot Study
Study Start Date : December 2011
Actual Primary Completion Date : February 2014
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 11C Acetate Imaging
11C acetate imaging
Other: 11C Acetate Imaging
Single scan

Primary Outcome Measures :
  1. Sensitivity of 11C Acetate PET [ Time Frame: 1 year ]
    Preliminarily demonstrate that the 11C acetate PET imaging of subjects who have experienced PSA relapse after prostatectomy for prostate cancer is more sensitive than currently available imaging techniques. Enrolled participants will have no evidence of recurrent disease on gold-standard imaging with CT abdomen/pelvis and 99mTc MDP bone scan (approximate sensitivity of 0%). The primary outcome is evidence of residual/recurrent disease as demonstrated by 11C acetate PET uptake outside of the prostatectomy bed.

Secondary Outcome Measures :
  1. Establish a Preliminary Institutional Experience with 11C Acetate Imaging [ Time Frame: 1 year ]
    To establish a preliminary institutional experience with 11C acetate imaging of men with prostate cancer

  2. Correlate 11C Acetate PET Imaging Findings with PSA Evidence of Response [ Time Frame: 1 year ]
    To descriptively correlate 11C acetate PET imaging findings with PSA evidence of response to subsequent salvage radiation therapy at 3 months and 6 months after the conclusion of radiation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • History of radical prostatectomy
  • Age ≥18 years
  • PSA ≥0.5 and <4.0 ng/mL
  • Abdominal-Pelvic CT scan without evidence of prostate cancer
  • 99mTc MDP bone scan without evidence of prostate cancer
  • Patient and clinician decision to proceed to salvage pelvic radiation therapy

Exclusion Criteria:

  • Presence of known extra-pelvic evidence of prostate cancer
  • Unable to fast for 4 hours
  • Uncontrolled diabetes
  • History of bilateral orchiectomies
  • Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01602783

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Umar Mahmood, MD, PhD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: Umar Mahmood, Principal Investigator, Massachusetts General Hospital Identifier: NCT01602783     History of Changes
Other Study ID Numbers: 10-464
First Posted: May 21, 2012    Key Record Dates
Last Update Posted: March 18, 2014
Last Verified: March 2014
Keywords provided by Umar Mahmood, Massachusetts General Hospital:
Radical Prostatectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases